Abstracts tagged "cytokines"

Abstract Number: 944 • 2013 ACR/ARHP Annual Meeting
Mir-125a: A Novel Regulator Of IL-6 and TLR Driven Pathways In RA Pathogenesis
Ashleigh-Ann Rainey¹, Derek S. Gilchrist², Clare E Tange¹, Marina Frleta³, Lynn Crawford², Derek Baxter², Iain B. Mcinnes⁴ and Mariola Kurowska-Stolarska⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Institute of infection, immunity and inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Molecular mechanisms driving disease initiation and chronicity in RA are incompletely understood. There is increasing interest in the role played therein by microRNAs –…
Abstract Number: 2573 • 2013 ACR/ARHP Annual Meeting
The Role Of STAT-3 In The Development Of Pulmonary and Dermal Fibrosis
Mesias Pedroza¹, Sarah To¹, Anuh T. George¹, David J. Tweardy² and Sandeep K. Agarwal¹, ¹Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX
Background/Purpose: Fibrosis is the accumulation of excessive extra-cellular matrix in tissues, leading to tissue damage. In systemic sclerosis, the trigger is postulated to be an…
Abstract Number: 1766 • 2013 ACR/ARHP Annual Meeting
Role Of IL33 In The Inflammation Of Takayasu Arteritis
David Saadoun¹, Marlène Garrido², Julien Gaudric³, Cloé Comarmond⁴, Michele Rosenzwacjg⁵ and Patrice Cacoub⁶, ¹Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ²I3 laboratory, Pitié-Salpétrière, Paris, France, ³Department of Vascular surgery GHPS, Paris, France, ⁴Internal Medicine and Clinical Imunology, Referal Center for Autoimmune diseases, Internal Medicine and Clinical Imunology, Hôpital Pitié Salpétrière, Paris, France, ⁵Department of Immunology GHPS, Paris, France, ⁶Médecine Interne 2, Hopital Pitié-Salpétrière, Paris, France
Background/Purpose: Interleukin (IL)-33, a member of the IL-1 cytokine family, is a recently described novel activator of endothelial cells, which promotes adhesion molecules and proinflammatory…
Abstract Number: 881 • 2013 ACR/ARHP Annual Meeting
Time To Renal Flare and Renal Disease Activity Over a 1 Year Period Is associated With Urinary TWEAK Levels In Patients With Systemic Lupus Erythematosus
Nicolas Wisniacki¹, Chris Stebbins², Jadwiga Bienkowska³, Susan Gawlak², Donald Bennett⁴, Yuhong Xiang⁵, Andrea Dearth⁶, Linda C. Burkly⁷, Ann Ranger⁶, Carrie Wager⁵, Laurence S. Magder⁸ and Michelle Petri⁹, ¹Medical Research, Biogen Idec, Maidenhead, United Kingdom, ²Translational Medicine, Biogen Idec, Cambridge, MA, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Biostatistics, Biogen idec, Cambridge, MA, ⁵Biostatistics, Biogen Idec, Cambridge, MA, ⁶Biogen Idec Inc, Cambridge, MA, ⁷Biogen Idec, Cambridge, MA, ⁸Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: TNF-like weak inducer of apoptosis (TWEAK) is a member of the TNF superfamily that signals through its distinct, highly inducible receptor, FGF-inducible molecule 14…
Abstract Number: 2537 • 2013 ACR/ARHP Annual Meeting
Inactive Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise
Luiz A. Perandini¹, Diego Sales-de-Oliveira¹, Suzana B.V. Mello², Niels O Camara³, Fernanda R. Lima¹, Eduardo F. Borba², Eloisa Bonfa², Ana Lucia Sá-Pinto¹, Hamilton Roschel⁴ and Bruno Gualano⁵, ¹University of Sao Paulo, Rheumatology Division, Sao Paulo, Brazil, ²University of Sao Paulo, Rheumatology Division, São Paulo, Brazil, ³Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil, ⁴Universidade de São Paulo, Faculdade de Educação Física e Esporte, São Paulo, Brazil, ⁵University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by a chronic inflammation associated with worse cardiovascular outcome. Although a few studies have…
Abstract Number: 1767 • 2013 ACR/ARHP Annual Meeting
Gender, Race, and Soluble Mediators Distinguish Blood Relatives Who Develop Incomplete Lupus Or Classified SLE In The Lupus Autoimmunity In Relatives (LAUREL) Study
Melissa E. Munroe¹, Kendra A. Young², Jill M. Norris², Joel M. Guthridge³, Diane L. Kamen⁴, Timothy B. Niewold⁵, Gary S. Gilkeson⁴, Michael H. Weisman⁶, Mariko L. Ishimori⁶, Daniel J. Wallace⁷, David R. Karp⁸, John B. Harley^9,10 and Judith A. James^11,12, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Healthy blood relatives (FDRs) of lupus…
Abstract Number: 842 • 2013 ACR/ARHP Annual Meeting
A Cytokine/Chemokine Multiplex Assay That Is Sensitive and Specific For Fibromyalgia Compared To Controls, Systemic Lupus Erythematosus, and Rheumatoid Arthritis
Daniel J. Wallace¹, Igor Gavin², Oleksiy Karpenko² and Bruce S. Gillis³, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of Illinois College of Medicine at Chicago, Chicago, IL, ³Department of Pathology, University of Illinois College of Medicine at Chicago, Chicago, IL
Background/Purpose: Fibromyalgia (FM) is a chronic pain and fatigue syndrome that affects about 6 million adults in the United States. The clinical diagnosis of…
Abstract Number: 2545 • 2013 ACR/ARHP Annual Meeting
Active Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise
Luiz A. Perandini¹, Diego Sales-de-Oliveira¹, Suzana B.V. Mello², Niels O Camara³, Fernanda R. Lima¹, Eduardo F. Borba², Eloisa Bonfa², Ana Lucia Sá-Pinto¹, Hamilton Roschel⁴ and Bruno Gualano⁵, ¹University of Sao Paulo, Rheumatology Division, Sao Paulo, Brazil, ²University of Sao Paulo, Rheumatology Division, São Paulo, Brazil, ³Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil, ⁴Universidade de São Paulo, Faculdade de Educação Física e Esporte, São Paulo, Brazil, ⁵University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is a rheumatic autoimmune condition characterized by altered lipoprotein profile, physical dysfunction and increased risk of cardiovascular disease. Exercise is,…
Abstract Number: 1685 • 2013 ACR/ARHP Annual Meeting
Long-Term Use Of Tocilizumab For The Treatment Of Giant Cell Arteritis
Sebastian Unizony¹, John Stone² and Brian Keroack³, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Maine Medical Center, Tufts University Medical School, Maine, ME
Background/Purpose: A sizeable percentage of giant cell arteritis (GCA) patients experience disease relapse upon glucocorticoid (GC) tapering, and a clearly effective GC-sparing alternative has not…
Abstract Number: 643 • 2013 ACR/ARHP Annual Meeting
Potential Immunopathological Roles Of The Novel Anti-Inflammatory Cytokine Interleukin-35 In Patients With Systemic Lupus Erythematous
Zhe Cai¹, Chun-Kwok Wong² and Lai Shan Tam³, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: IL-35, a dimeric protein with two subunits, IL-12A (p35) and Epstein-Barr virus induced 3, is a novel IL-12 cytokine family regulatory T-cells (Treg)-specific immunosuppressive/anti-inflammatory…
Abstract Number: 2499 • 2013 ACR/ARHP Annual Meeting
Analysis Of Inflammatory Markers Within Facet Joints Of Patients Within Ankylosing Spondylitis
Uta Syrbe¹, Janine Bleil², Rene Maier³, Heiner Appel¹ and Joachim Sieper⁴, ¹Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, ²Charité, Berlin, Germany, ³Charite, Berlin, Germany, ⁴Charitè Campus Benjamin Franklin, Berlin, Germany
Background/Purpose: Inflammation within sacroiliac joints and within the spine is a hallmark of ankylosing spondylitis (AS). Apart from nonsteroidal anti-rheumatic drug (NSAID) treatment, inhibition of…
Abstract Number: 1691 • 2013 ACR/ARHP Annual Meeting
The STAT1 Signaling Pathway In Giant Cell Arteritis
Bjorn Hartmann¹, Joyce Liao², Michael H. Weisman³, Kenneth J. Warrington⁴, Jorg J. Goronzy¹ and Cornelia M. Weyand⁵, ¹Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Byers Eye Institute at Stanford, Stanford University, Palo Alto, CA, ³Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁵Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: In giant cell arteritis (GCA), CD4 T cells, macrophages and multinucleated giant cells form granulomatous lesions in the walls of medium and large arteries.…
Abstract Number: 635 • 2013 ACR/ARHP Annual Meeting
Multiple Altered Soluble Inflammatory Mediators Correlate With Disease Activity and Mark Impending Disease Flare In European-American Lupus Patients
Melissa E. Munroe¹, Jourdan R. Anderson², Krista M. Bean³, Joan T. Merrill⁴, Joel M. Guthridge³, Virginia C. Roberts³, Linda F. Thompson^5,6 and Judith A. James^4,7, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Immunobiology and Cancer, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE is a waxing and waning disease characterized by immune dysregulation, major organ involvement, and disease flares. Identifying mechanistic mediators of altered disease activity…
Abstract Number: 2423 • 2013 ACR/ARHP Annual Meeting
Mir-27b As Biomarker and Regulator Of IL-6R Pathway In Resistant Rheumatoid Arthritis Monocyte
Marina Frleta¹, Ashleigh-Ann Rainey², Derek S. Gilchrist³, Lynn Crawford³, Derek Baxter³, Mariola Kurowska-Stolarska⁴ and Iain B. McInnes², ¹Institute of infection, immunity and inflammation, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Whereas molecular mechanisms mediating treatment responses to biologic DMARDS in Rheumatoid Arthritis (RA) are emerging, those pathways that subserve treatment resistance are poorly explored.…
Abstract Number: 1683 • 2013 ACR/ARHP Annual Meeting
High Prevalence Of Metabolic Syndrome In Takayasu Arteritis: An Increased Cardiovascular Risk and Lower Adiponectin Serum Levels
Thiago Silva¹, Mauricio Levy-Neto², Rosa M. R. Pereira³ and Eloisa Bonfa⁴, ¹Rheumatology Division, University of São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ³Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Universidade de Sao Paulo, São Paulo, Brazil
Background/Purpose: The prevalence of Metabolic Syndrome (MetS) tends to be high among rheumatic patients, and cardiovascular disease is the leading cause of death in these…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].